AXIS Capital's shares had a "remarkable two years," Joshua Shanker said in the downgrade note. The next two years will be different, he says.

The FDA gave priority review to an application seeking approval of AXS-05 for Alzheimer's-related agitation, with a decision ...

AXIS Capital (AXS) falls after BofA downgrade to Neutral, citing weaker insurance pricing trends and less transparent ...

Shares of Axis Capital Holdings AXS have gained momentum. The stock is trading above its 50 and 200-day simple moving average ...

AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two ...

The sNDA for AXS-05 for Alzheimer disease agitation includes findings from four phase 3 trials showing improved behaviors and delayed relapse.

Axsome Therapeutics recently reported that the FDA accepted its supplemental application and granted priority review for AXS-05 to treat agitation in Alzheimer’s disease, while also confirming that ...

Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...

New Drug Application (NDA) submission on track for January 2026NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: ...